Hayakawa Mikito
Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Front Neurol Neurosci. 2015;37:62-77. doi: 10.1159/000437114. Epub 2015 Nov 12.
The efficacy of intravenous thrombolysis (IVT) for acute ischemic stroke patients has been well established worldwide, with endovascular therapy performed in patients who have failed or are ineligible for IVT and who have major vessel occlusion. The most feared complication of acute stroke reperfusion therapy is intracerebral hemorrhage (ICH), as these patients have a poor clinical outcome and high mortality. The fundamental mechanisms responsible for reperfusion-related ICH include increased permeability and disruption of the blood-brain barrier. Recombinant tissue plasminogen activator may exacerbate the blood-brain barrier disruption through its pharmacological action during IVT. Furthermore, interactions between the device and the vessel walls and contrast intoxication may also be related to ICH, which includes the occurrence of subarachnoid hemorrhage after endovascular therapy. Numerous factors have been reported to be associated with or to be able to predict ICH, and several scoring systems have been developed for predicting symptomatic ICH (sICH) after IVT. However, a scoring system with enough power to detect an unacceptably high risk of sICH or to provide information on when to withdraw IVT has yet to be definitively established. In current clinical practice, acute stroke patients without contraindications for IVT who have been identified by conventional computed tomography scans normally undergo IVT, irrespective of any clinical predictors of ICH after IVT. Strategies that have been suggested for preventing reperfusion-related ICH in high-risk patients include intensive blood pressure control, tight glycemic control, and the avoidance of early aggressive antithrombotic therapy. If sICH, and especially massive parenchymal hematoma, does occur, hematoma expansion needs to be prevented through the use of tight blood pressure control and other methods. Although evidence of efficacy has yet to be established, surgical removal is performed not only for the purpose of saving lives but also for improving the functional outcome. In order to develop therapeutic strategies for reperfusion-related ICH that will lead to an improved stroke prognosis, further studies are warranted.
静脉溶栓(IVT)治疗急性缺血性脑卒中患者的疗效在全球范围内已得到充分证实,对于IVT失败或不适合IVT且存在大血管闭塞的患者,则进行血管内治疗。急性脑卒中再灌注治疗最可怕的并发症是脑出血(ICH),因为这些患者临床预后差且死亡率高。与再灌注相关的ICH的根本机制包括血脑屏障通透性增加和破坏。重组组织型纤溶酶原激活剂在IVT期间可能通过其药理作用加剧血脑屏障破坏。此外,器械与血管壁之间的相互作用以及造影剂中毒也可能与ICH有关,这包括血管内治疗后蛛网膜下腔出血的发生。据报道,许多因素与ICH相关或能够预测ICH,并且已经开发了几种评分系统来预测IVT后症状性ICH(sICH)。然而,一个有足够能力检测出不可接受的高sICH风险或提供何时停止IVT信息的评分系统尚未最终确立。在当前临床实践中,经传统计算机断层扫描确定无IVT禁忌证的急性脑卒中患者通常接受IVT,而不考虑IVT后ICH的任何临床预测因素。对于预防高危患者再灌注相关ICH所建议的策略包括强化血压控制、严格血糖控制以及避免早期积极的抗栓治疗。如果确实发生了sICH,尤其是大量脑实质血肿,则需要通过严格控制血压和其他方法来预防血肿扩大。尽管疗效证据尚未确立,但手术清除不仅是为了挽救生命,也是为了改善功能结局。为了制定能改善脑卒中预后的再灌注相关ICH的治疗策略,有必要进行进一步研究。